Sulforaphane has one of the more developed human clinical trial records among plant-derived supplement compounds, largely because a research group at Johns Hopkins spent over a decade building a case for it in cancer chemoprevention before its scope expanded into neuropsychiatric conditions like autism and schizophrenia.
Here’s what the actual trial data shows, separated from the broader marketing claims that often surround broccoli sprout extract products.
Key Takeaways
- A comprehensive 2025 review identified 84 total sulforaphane trials, with 39 published; roughly a third of the published human brain-disorder trials cover autism spectrum disorder, schizophrenia, or fragile-X-associated conditions [1].
- The best-known autism trial found a 34% decline in Aberrant Behavior Checklist scores and a 17% decline in Social Responsiveness Scale scores in young men given sulforaphane over several weeks [2].
- Randomized trials in schizophrenia patients have tested sulforaphane’s effect on negative symptoms and cognition, based on the rationale that oxidative stress contributes to the disorder [3].
- Across trials, sulforaphane’s safety profile has been favorable, with mild GI symptoms as the most commonly reported issue and no serious adverse events consistently linked to it [1].
- Most published human trials remain small (dozens, not thousands, of participants), so results should be read as promising signals rather than settled conclusions.
Autism Spectrum Disorder: The Most-Studied Application
The landmark trial in this space was a double-blind, placebo-controlled study in young men with autism spectrum disorder, which reported a 34% average decline in Aberrant Behavior Checklist scores and a 17% decline in Social Responsiveness Scale scores over the treatment period [2]. Subsequent randomized trials, including a 36-week phase 2 trial in children ages 3–12 using glucoraphanin-rich broccoli seed extract, have tested whether these findings replicate in younger populations, with mixed results across different age groups and dosing protocols [1].
Schizophrenia: An Emerging but Earlier-Stage Line of Research
Researchers extended the autism rationale to schizophrenia based on shared oxidative-stress and neuroinflammation pathways between the two conditions. A randomized, double-blind trial examined sulforaphane’s effects on cognition and symptoms in patients with first and early-episode schizophrenia [3], and later trials have looked at negative symptoms and cognitive impairment in chronic schizophrenia. This body of work is smaller and newer than the autism literature, and results on symptom improvement have been more modest and inconsistent.
What a 2025 Review of the Full Trial Landscape Found
A comprehensive analysis tracked 84 total registered sulforaphane trials, of which 39 had published results at the time of review, with 19 of those trials focused specifically on brain disorders including autism, fragile-X-associated tremor/ataxia syndrome, and schizophrenia [1]. The review’s overall conclusion was that sulforaphane demonstrated real symptomatic improvements in some brain-disorder trials but that biomarker integration — objectively confirming the biological mechanism was actually engaged in those patients — remains weak across the field.
Safety Signal Across Trials
Across the published human trials, sulforaphane and glucoraphanin-rich broccoli extracts have shown a consistently mild adverse-event profile, with gastrointestinal symptoms like indigestion or loose stools being the most commonly reported issue rather than anything more serious [1].
Reading Trial Results Honestly
It’s worth being direct about scale: most sulforaphane human trials, including the widely cited autism study, involve dozens of participants rather than the hundreds or thousands typical of a drug approval trial. That doesn’t make the findings meaningless, but it does mean they’re better understood as promising early clinical signals that justify further, larger research — not as proof that sulforaphane treats any diagnosed condition.
Frequently Asked Questions
Has sulforaphane been approved by the FDA to treat any condition?
No. Sulforaphane is sold as a dietary supplement, not an approved drug, and no supplement in this category is FDA-evaluated to treat, cure, or prevent disease.
Are the autism and schizophrenia trials the same as saying sulforaphane ‘works’ for these conditions?
No. They show statistically measurable changes on specific rating scales in controlled trial settings, which is meaningfully different from a proven, universally effective treatment. Talk to a physician before using sulforaphane as an adjunct for any diagnosed condition.
How large were these trials, realistically?
Small by pharmaceutical standards — typically tens of participants per arm, which is enough to detect a signal worth further study but not enough to be considered definitive.
References
- Saito et al., Journal of Nutritional Science (2025). Sulforaphane as a potential therapeutic agent: a comprehensive analysis of clinical trials and mechanistic insights. pubmed.ncbi.nlm.nih.gov/40988712…
- Zimmerman et al., Molecular Autism (2021). Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. ncbi.nlm.nih.gov/pmc/articles/PMC8146218…
- Hei et al., Schizophrenia Bulletin Open (2022). Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial. academic.oup.com/schizbullopen/article/3/1/sgac024…
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
